A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.

Trial Profile

A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2012

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Aluminium hydroxide
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 30 Jul 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 12 Sep 2011 Results presented at the Fourth ESWI Influenza Conference, according to a Medicago media release.
    • 30 Jun 2011 Final phase II results have been reported in a Medicago media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top